Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Freeline Therapeutics Holdings plc is a biotechnology business based in the US. Freeline Therapeutics shares (FRLN) are listed on the NASDAQ and all prices are listed in US Dollars. Freeline Therapeutics employs 236 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $1.41 |
|---|---|
| 52-week range | $1.37 - $18.49 |
| 50-day moving average | $2.30 |
| 200-day moving average | $5.67 |
| Wall St. target price | $12.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-4.03 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.41 from 2022-01-20
| 1 week (2022-01-14) | -4.08% |
|---|---|
| 1 month (2021-12-22) | -31.55% |
| 3 months (2021-10-22) | -55.24% |
| 6 months (2021-07-22) | -73.09% |
| 1 year (2021-01-22) | -92.25% |
|---|---|
| 2 years (2020-01-18) | N/A |
| 3 years (2019-01-18) | N/A |
| 5 years (2017-01-18) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -38.3% |
| Return on equity TTM | -71.42% |
| Profit margin | 0% |
| Book value | $4.27 |
| Market capitalisation | $52.6 million |
TTM: trailing 12 months
We're not expecting Freeline Therapeutics to pay a dividend over the next 12 months.
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. .
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.